Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

The business may not be as strong as its performance this year suggests.

The next major drugmaker interested in what Repertoire has to offer is Eli Lilly, which has thrown down $85 million upfront and floated up to $1.84 billion more in biobucks to collaborate on potential ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

As part of the deal, Repertoire Immune Medicines will develop up to three drug candidates that target the drivers of certain autoimmune diseases.

Michael Chain Jr. once had to exit the Pennsylvania Turnpike at Downingtown and drive a zigzag pattern on State Routes 100, 113, 401, and 29 to reach his hotel. So did his customers. But then the ...

Moderna (NasdaqGS:MRNA) is shifting away from self-funding new Phase III vaccine trials in response to increased vaccine ...

Jan 29 (Reuters) - Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies for multiple autoimmune diseases, the Massachusetts-based ...

By Christy Santhosh Jan 29 (Reuters) - Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up ...

One way leads to a future in which AI-driven breakthroughs remain the exclusive domain of pharmaceutical giants with billion-dollar budgets. The other, to a landscape where breakthroughs regularly ...

Repertoire Immune Medicines partners with Eli Lilly to develop tolerizing therapies for autoimmune diseases, receiving $85 ...

Roivant Sciences (ROIV) is up ~110% in 6 months, but still has no product revenue. Read here for a detailed investment ...